Brief: Puma Biotechnology Presents Final Results From Biliary Tract Cohort Of Phase 2 Summit 'Basket' Trial Of Neratinib
04/06/2022 16:08
June 4 (Reuters) - Puma Biotechnology Inc PBYI.O :
* PUMA BIOTECHNOLOGY PRESENTS FINAL RESULTS FROM THE BILIARY
TRACT
COHORT OF THE PHASE 2 SUMMIT ‘BASKET’ TRIAL OF NERATINIB AT THE
ASCO 2022 ANNUAL MEETING
* ADDITIONAL STUDIES ARE NEEDED TO DETERMINE IF COMBINING
NERATINIB WITH OTHER CANCER THERAPIES COULD SIGNIFICANTLY EXTEND
SURVIVAL
Source text for Eikon: ID:nBw8dqW73a
Further company coverage: PBYI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Puma Biotechnology
See all newsBrief: Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(C)(4)
Brief: Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)
Puma Biotechnology Inc reports results for the quarter ended June 30 - Earnings Summary
Corrected: Puma Biotechnology lifts 2026 outlook as Q2 revenue rises on NERLYNX demand
Brief: Puma Biotechnology Q2 Adjusted EPS USD 0.2